|
| 2 | EFFICACY OF LOPINAVIR/RITONAVIR IN 104 MULTIPLE PI-EXPERIENCED PATIENTS ACCORDING TO MUTATIONAL PATTERNS: DATA FROM THE FRENCH ATU PROGRAM European AIDS Conf 2001 Oct 28-31;8: F1/2 (abstract no. 2) V Calvez1, I Cohen-Codar2, AG. Marcelin1, G. Peytavin3, D Descamps1, J Ritter1, C Tamalet1, M Segondy1, H Peigue-Lafeuille1, E. Guillevic2, R Rode4, J Isaacson4, D Kempf4, JP Chauvin2 A virologic and immunologic response to LPV/r was obtained, even in these heavily pretreated patients. A lopinavir mutation score of 0-5 vs. ≥ 6 was the clinically relevant genotypic breakpoints for an optimal efficacy of LPV/r observed in this cohort, which is consistent with the findings from other previous trials. |
| 12 | VIROLOGICAL AND IMMUNOLOGICAL OUTCOME IN 109 PATIENTS WITH WELL CONTROLLED VIRAL REPLICATION WHO SWITCHED FROM A PI-INCLUDING TO A PI-SPARING REGIMEN European AIDS Conf 2001 Oct 28-31;8: (abstract no. 12) S. Melzi, F. Adorni, B. Castelnuovo, E. Chiesa, M. Bongiovanni, T. Bini, F. Tordato, A. d’Arminio Our study demonstrates that switching from a PI-including to a PI-sparing regimen, in subjects with well controlled viral replication, has to be carefully valuated. In fact, only cases with a long term control of viral replication on PI-including regimens can obtain mainteinance of virological success. The higher risk of virological failure in patients on NVP might be also attributable to a higher frequency of therapy discontinuation due to cutaneous adverse events. |
| 13 | LONG-TERM FOLLOW UP OF A RANDOMISED CLINICAL TRIAL COMPARING 2 FIRST-LINE PROTEASE INHIBITOR CONTAINING TREATMENT REGIMENS (IRIS STUDY). European AIDS Conf 2001 Oct 28-31;8: (abstract no. 13) E.Florence1, C.Dreezen1, P.Desmet1, B. Vandercam2, N.Clumeck3, R.Colebunders1 After 3 years, most pts on a RTV/SQV or IDV containing first line PI treatment regimen switched to other combinations. The majority of them had a high CD4+ lymphocyte count and a good virological response similarly in both arms. |
| 14 | BONE TURNOVER IN CHILDREN WITH CONNATAL HIV INFECTION European AIDS Conf 2001 Oct 28-31;8: (abstract no. 4) S. Bertelloni1, L. Titone2, A. Liotta3;, G. I. Baroncelli1, A. Romano3, M. C. Maggio2, P. Di Carlo3, P. M. Miraglia3 Authors conclude that important dispersion of examined results and frequency of pathological levels of tested bone markers are not consensual with literature data about adult patients. It is possible due to extreme clinical variability of HIV syndrome in childhood, that is why every child could manifest a particular clinical and haematological evolution, with an individual bone turnover. |
| 16 | PRE-TREATMENT WITH INTERFERON-ALPHA + RIBAVIRIN OF HIV-HCV COINFECTED PATIENTS APPEARS TO REDUCE HEPATOTOXICITY ASSOCIATED WITH SUBSEQUENT ANTIRETROVIRAL DRUGS European AIDS Conf 2001 Oct 28-31;8: (abstract no. 16) C. Uberti-Foppa, A.De Bona, R. Finazzi, G.Sitia, G.Morsica, E.Boeri, F.Veglia and A.Lazzarin Our data indicate that in HIV-HCV coinfected subjects with CAH, anti-HIV drug-induced hepatotoxicity is significantly reduced (from 2 to 3 times) by anti-HCV pretreatment, even in absence of a long-term hepatitis C virological response. |
| 427 | HIV CLINICAL RESEARCH: A PERSPECTIVE FROM THE PATIENT COMMUNITY European AIDS Conf 2001 Oct 28-31;8: (abstract no. 427) Jorma Koskinen [I]t could be safely said that the cooperation between the patient community on the one hand and clinicians, scientists, regulation authorities, conference organisers and pharmaceutical industry on the other hand has come of age. Well-established working relationships exist between patients and the world of clinical research and they should be further developed and strengthened. |
| 428 | EVOLUTION OF HIV RELATED MALIGNANCIES IN 2001 European AIDS Conf 2001 Oct 28-31;8: (abstract no. 428) Eric OKSENHENDLER The relative risk of developing an HIV associated malignancy remains high and an increased relative morbidity and mortality is associated with these tumors. As therapies improve the survival of AIDS patients, the cumulative risk of developing or dying from cancer is likely to increase. |
| 429 | INITIAL TREATMENT STRATEGY FOR CHRONIC HIV INFECTION European AIDS Conf 2001 Oct 28-31;8: (abstract no. 429) Professor B G Gazzard It is recognized that most individuals will require more than one regimen during their lifetime and the ability of the first regimen to be successfully salvaged by a second would also be an important aspect of choosing therapy. Again strategic studies are now addressing this issue. |
| 430 | HIV AND HEPATITIS C VIRUS COINFECTION European AIDS Conf 2001 Oct 28-31;8: (abstract no. 430) Angelos Hatzakis The currently recommended treatment for HCV/HIV is combination of interferon-a plus ribavirin. However, additive toxicity, pharmacological interactions and poor adherence may compromise the treatment of chronic HCV/HIV coinfection. New treatment strategies that include pegylated interferons with dual efficacy against both HIV and HCV are currently under evaluation. |
| 431 | FAILURE IN EARLY STAGE OF THERAPY European AIDS Conf 2001 Oct 28-31;8: (abstract no. 431) B. Hirschel The outlook for antiretroviral-naïve patients on HAART continues to improve. With multiple changes in therapy, 70 to 80 percent of patients have satisfactory control of viremia four to five years after starting therapy. |
| 432 | VACCINES AGAINST HIV: PRESENT AND FUTURE European AIDS Conf 2001 Oct 28-31;8: (abstract no. 432) José Esparza In order to accelerate HIV vaccine development, additional candidate vaccines must be evaluated in parallel in industrialized and developing countries, and that will require intense international collaboration and coordination. Critical ethical issues need to be carefully considered and addressed in the implementation of these international trials. It is also imperative to start planning now how to use future HIV vaccines, to ensure that they contribute to the overall HIV/AIDS prevention effort. |
| 433 | LIPODYSTROPHY/METABOLIC SYNDROMES European AIDS Conf 2001 Oct 28-31;8: (abstract no. 433) Esteban Martinez Investigational therapies have mainly consisted of general health measures (diet and exercise), switching antiretrovirals (from protease inhibitors to non-nucleoside reverse transcriptase inhibitors or abacavir, or from stavudine to other nucleoside reverse transcriptase inhibitors), and use of drugs with metabolic effects (metformin, thiazolidinediones, recombinant growth hormone, and anabolic steroids). A judicious use of available data from an individualised approach seems the best option to manage this problem at present. |
| 434 | WHEN AND HOW TO USE THERAPEUTIC DRUG MONITORING European AIDS Conf 2001 Oct 28-31;8: (abstract no. 434) David Burger The Dutch Athena study has shown that TDM of nelfinavir and indinavir in treatment-naïve patients improves the outcome after one year of follow-up. A couple of other TDM studies are now ongoing and will show us how to use TDM in clinical practice. |
| 435 | EUROPEAN TREATMENT GUIDELINES European AIDS Conf 2001 Oct 28-31;8: (abstract no. 435) N. Clumeck These guidelines attempt to summarize the current state of knowledge of HIV disease management and treatment which is a rapidly evolving medical field and will therefore require regular change and update in the coming years. |
| 436 | PROMISING NEW DRUGS European AIDS Conf 2001 Oct 28-31;8: (abstract no. 436) Murphy, Robert The new agents in development are likely to provide further options and significant benefit for patients initiating therapy and for those requiring therapy following treatment failure. |
| 437 | WHEN AND HOW TO USE RESISTANCE TESTING IN PATIENT MANAGEMENT? European AIDS Conf 2001 Oct 28-31;8: (abstract no. 437) F. Brun-Vézinet and the ANRS Resistance Group Genotype interpretation is usually based on rules-based algorithms. Different interpretation systems exist with substantial variability in performances. The clinically relevant genotype interpretation systems are based on correlation study analyzing the profile of mutations at baseline and the virological response in treated patients. |
| 438 | TENOFOVIR DISOPROXIL FUMARATE – A NOVEL NRTI IN PHASE III CLINICAL DEVELOPMENT European AIDS Conf 2001 Oct 28-31;8: (abstract no. 438) James F Rooney, Dion Coakley, Andrew Cheng, Carol Brosgart, Michael Miller Gilead Sciences In the long term management of HIV infection, new antiretroviral agents that can be easily administered and are capable of providing sustained activity with little or no selection of drug resistance are needed to ensure durable viral suppression and to preserve future treatment options. Tenofovir DF will be a valuable new addition to current therapies and should provide benefit to both treatment naïve and treatment experienced patients. |
| 439 | DUPONT PHARMACEUTICALS COMPANY ANTI-HIV COMPOUNDS IN DEVELOPMENT European AIDS Conf 2001 Oct 28-31;8: (abstract no. 439) Douglas J. Manion MD DuPont is actively searching for new nucleoside analogs with activity against mutants conferring resistance to currently available agents. The first such candidate is DPC 817 which began dosing in humans earlier this year. |
| 440 | CHARACTERIZATION OF GW 908/VX 175, A NEW PROTEASE INHIBITOR EVALUATED IN VARIOUS CLINICAL SETTINGS European AIDS Conf 2001 Oct 28-31;8: (abstract no. 440) R Tung1, A Spaltenstien2, J Millard2, S Gharakhanian1, J Pottage1, J Yeo2, E Furfine2 GW908 is a significant advance in the simplification of PI therapy allowing for incorporation of a potent and safe agent within HAART regimens. Studies with GW908 are currently evaluating pharmacoenhancement with ritonavir, OD dosing, comparison vs. nelfinavir in treatment-naïve and vs. lopinavir in pre-treated patients as well as prospective evaluation of lipodystrophy/metabolic parameters. |
| 441 | TARGETING HIV FUSION: CLINICAL RESULTS WITH T-20 AND T-1249 European AIDS Conf 2001 Oct 28-31;8: (abstract no. 441) F. Duff1, M. Salgo1, J. Delehanty2 and D. Miralles2 The potential for once-daily T-1249 administration was supported by pharmacokinetic analyses. T-1249 was well tolerated; mild local injection site reactions were the most frequent adverse event (40%). Higher doses are under investigation. |
| 442 | THE DEVELOPMENT OF THE NEXT GENERATION OF ANTIRETROVIRALS WITH ACTIVITY AGAINST DRUG-RESISTANT STRAINS OF HIV-1 European AIDS Conf 2001 Oct 28-31;8: (abstract no. 442) R Pauwels HIV-1 site-directed mutants with classical PI mutations exhibit reduced fitness in the presence of the compounds, raising the possibility that these inhibitors represent a new class of ‘resistant-repellent’ compounds that are able to prevent or delay the development of PI-resistance. |
| 2 | EFFICACY OF LOPINAVIR/RITONAVIR IN 104 MULTIPLE PI-EXPERIENCED PATIENTS ACCORDING TO MUTATIONAL PATTERNS: DATA FROM THE FRENCH ATU PROGRAM European AIDS Conf 2001 Oct 28-31;8: (abstract no. 2) V Calvez1, I Cohen-Codar2, AG. Marcelin1, G. Peytavin3, D Descamps1, J Ritter1, C Tamalet1, M Segondy1, H Peigue-Lafeuille1, E. Guillevic2, R Rode4, J Isaacson4, D Kempf4, JP Chauvin2 A virologic and immunologic response to LPV/r was obtained, even in these heavily pretreated patients. A lopinavir mutation score of 0-5 vs. ≥ 6 was the clinically relevant genotypic breakpoints for an optimal efficacy of LPV/r observed in this cohort, which is consistent with the findings from other previous trials. |
| 5 | NON OCCUPATIONAL POST EXPOSURE PROPHYLAXIS (NONOPEP) FOR HIV IN EUROPE: REVIEW OF POLICIES AND IMPLEMENTATION OF AN EUROPEAN REGISTRY European AIDS Conf 2001 Oct 28-31;8: (abstract no. 5) J. Almeda, J. Casabona, B. G. Simon, and for the NONOPEP Working Group: E. Bernasconi, M. Gerard, A. Mota Miranda, V. Puro, D. Rey, G. Sonder, J.Tomazic In the majority of the european countries, there are neither national guidelines nor national registry on NONOPEP. The number not negligible of cases already collected by the existing registries, confirm that the demand of NONOPEP is indisputable. The risk evaluation, the indication and the type of treatment are very variable. The question about the effectiveness, the feasability and the european standardization of the policies of the non occupational post exposure prophylaxis for HIV is still a topical question and justifies the need of an European Registry to collect and analyse the data of the patients who consult for a NONOPEP. |
| 12 | VIROLOGICAL AND IMMUNOLOGICAL OUTCOME IN 109 PATIENTS WITH WELL CONTROLLED VIRAL REPLICATION WHO SWITCHED FROM A PI-INCLUDING TO A PI-SPARING REGIMEN European AIDS Conf 2001 Oct 28-31;8: (abstract no. 12) S. Melzi, F. Adorni, B. Castelnuovo, E. Chiesa, M. Bongiovanni, T. Bini, F. Tordato, A. d’Arminio Monfortez Our study demonstrates that switching from a PI-including to a PI-sparing regimen, in subjects with well controlled viral replication, has to be carefully valuated. In fact, only cases with a long term control of viral replication on PI-including regimens can obtain mainteinance of virological success. The higher risk of virological failure in patients on NVP might be also attributable to a higher frequency of therapy discontinuation due to cutaneous adverse events. |
| 13 | LONG-TERM FOLLOW UP OF A RANDOMISED CLINICAL TRIAL COMPARING 2 FIRST-LINE PROTEASE INHIBITOR CONTAINING TREATMENT REGIMENS (IRIS STUDY) European AIDS Conf 2001 Oct 28-31;8: (abstract no. 13) E. Florence1, C. Dreezen1, P. Desmet1, B. Vandercam2, N. Clumeck3, R. Colebunders1 After 3 years, most patients on a RTV/SQV or IDV containing first line PI treatment regimen switched to other combinations. The majority of them had a high CD4+ lymphocyte count and a good virological response similarly in both arms. |
| 14 | BONE TURNOVER IN CHILDREN WITH CONNATAL HIV INFECTION European AIDS Conf 2001 Oct 28-31;8: (abstract no. 14) S. Bertelloni1, L. Titone2, A. Liotta3, G. I. Baroncelli1, A. Romano2, M. C. Maggio3, P. Di Carlo2, P. M. Miraglia2 Authors conclude that important dispersion of examined results and frequency of pathological levels of tested bone markers are not consensual with literature data about adult patients. It is possible due to extreme clinical variability of HIV syndrome in childhood, that is why every child could manifest a particular clinical and haematological evolution, with an individual bone turnover. |
| 20 | ELEVATED AMMONIA LEVELS IN HIV-INFECTED PATIENTS ON HAART: A PILOT STUDY European AIDS Conf 2001 Oct 28-31;8: (abstract no. 20) Sheetal Sharma1, Antonia Zapantis2, Kathleen K. Graham1,2 Patients on HAART complaining of the triad of lethargy, fatigue and slow mentation, demonstrated clinically significantly elevated ammonia levels with otherwise normal metabolic studies. Ammonia levels and clinical symptoms improved following treatment with lactulose. Further study is required to evaluate elevated ammonia levels in HIV-infected patients receiving HAART. |
| 21 | COMBINATION THERAPY IN HIV-1 INFECTED PREGNANT WOMEN. ANALYSIS OF THERAPEUTICAL CHOICES AND EVALUATION OF SHORT TERM EFFECTS ON MOTHER AND BABY European AIDS Conf 2001 Oct 28-31;8: (abstract no. 21) E. Visconti1, L. Pastore Celentano1, S. Marinaci, P. Villa2, G. Oliva2, C. Fundarò3, O. Genovese3, E. Tamburrini1 Therapeutical choices in pregnancy should be tailored considering both the efficacy for the HIV infected mother (during pregnancy and future options) and safety for the baby. In particular, long time effects should be carefully considered, and a follow up is ongoing on this issue. The use of combined protocols seems well responsive to these two issues. |
| 25 | LYMPHOCYTE FUNCTION IN HIV-INFECTION COMPARED TO HEART-TRANSPLANT RECIPIENTS European AIDS Conf 2001 Oct 28-31;8: (abstract no. 25) T Rath, V Oliveira1, A Klein1, B Thiele2, H Zankl1, F W Albert When compared to patients under immunosuppressive therapy a marked reduction of CD4-cells in HIV-pts can be found, but the cytokine response after stimulation with CMV and TBC showed no difference. Only stimulation with TeT discloses a tendency to increased TNF-α levels and only mitogenic stimulation with PWM reveals IL-2 and IL-10 deficiency in HIV-pts. |
| 29 | DISSEMINATED INFECTION DUE TO STRONGYLOIDES STERCORALIS IN AIDS PATIENTS European AIDS Conf 2001 Oct 28-31;8: (abstract no. 29) Corti M., Trione N., Valerga M., Abuin J. S. stercoralis is an important cause of severe dissemination disease and death in AIDS patients. The absence of peripheral blood eosinophilia was associated with a poor prognosis and a short survival in this cohort of patients. We recommend and aggressive examination of stool, duodenal aspirates and sputum in-patients at risk for the disease. Secondary infections are common; treatment should be continued until viable parasites have been eradicated. Because of the high relapse rate, we considerate appropriate a close follow-up of these patients and, eventually, a secondary prophylaxis should be indicated. |
| 30 | KALETRA® PRE-REGISTRATIONAL USAGE IN FRANCE (ATU) : A 2000 TO 2001 INSIGHT INTO THE THERAPEUTIC TRENDS AND OUTCOMES IN HIV TREATMENT-EXPERIENCED PATIENTS European AIDS Conf 2001 Oct 28-31;8: (abstract no. 30) I. Cohen-Codar, F. Boer, R. Terrier, E. Guillevic, D. Pellier, P. Ngo Van, JP. Chauvin The extensively treated patients who needed the pre-registrational prescription of Kaletra were moderately immunodeficient. Most subjects were no longer naïve to at least 3 PIs and 4 NRTIs and presented with a high prevalence of more than 5 mutations on HIV RT or Protease genes. |
| 32 | STUDY OF THE INITIAL RESPONSE TO KALETRA® IN HIV TREATMENT-EXPERIENCED PATIENTS: THE ATU PRE-REGISTRATIONAL COHORT IN FRANCE European AIDS Conf 2001 Oct 28-31;8: (abstract no. 32) P. Ngo Van, I. Cohen-Codar, F. Boer, R. Terrier, D. Pellier, E. Guillevic, JP. Chauvin In heavily treatment-experienced patients, Kaletra® can achieve a relevant virological and immunological effect, even when up to 5 PI mutations are present. However, subjects with multiple PI experience seem to have a poorer response. |
| 53 | INCIDENCE OF ADVERSE REACTIONS IN HIV PATIENTS TREATED WITH PROTEASE INHIBITORS: THE CISAI STUDY European AIDS Conf 2001 Oct 28-31;8: (abstract no. 53) Bonfanti P, Quirino T, Faggion I, Valsecchi L, Carradori S, Pusterla L, Fortuna P, Timillero L, Miccolis S, Magnani C, Gabbuti A, Cinelli R, Landonio S, Vigevani GM Ritonavir, either alone or associated with SQV-HGC, is the PI that most frequently generates adverse events in the HAART-treated population, while SQV-HGC is the best in terms of tolerability. If we consider only serious events, Nelfinavir has the lowest incidence rate. We are now particularly focusing our attention on the unexpected and rare adverse events reported in our cohort, such as osteonecrosis, that could lead to serious physical impairment if unrecognized. |
| 77 | T-CELL VACCINATION IN HIV INFECTION – A PHASE 1 CLINICAL TRIAL European AIDS Conf 2001 Oct 28-31;8: (abstract no. 77) R. Abulafia-Lapid, Z. Bentwich, Y. Keren-Zur, I. Cohen, H. Atlan Though this is only a phase 1 clinical trial, designed to evaluate safety and feasibility, it offers a novel approach for the treatment of HIV infection which will have to be tested in a larger number of patients. We are now emabarking on such a trial. |
| 78 | VERTICAL TRANSMISSION OF HEPATITIS C VIRUS IN CHILDREN BORN TO CO-INFECTED WITH HIV-1 AND HCV WOMEN European AIDS Conf 2001 Oct 28-31;8: (abstract no. 78) Zverev Sergei, Novikova O.V., Zemskova E.A. In our experience none of children born to women co-infected with HIV-1 and HCV were dually infected. Risk of possible vertical transmission of both viruses simultaneously in such babies requires development and realizing effective prophylactic measures. |
| 79 | TUBERCULOSIS AND MYCOBACTERIOSIS IN AIDS PATIENTS: APPLICATION AMLIFIED MYCOBACTERIUM TUBERCULOSIS DIRECT TEST, ACCU PROBE AND MB/BacT AFB SYSTEM FOR THE ENHANCED DIAGNOSIS OF TUBERCULOSIS European AIDS Conf 2001 Oct 28-31;8: (abstract no. 79) Zalewska-Schonthaler N., Schonthaler-Humiêcka J., Podlasin R., Cholewiñska G., Miku£a T., Grubek-Jaworska H., Horban A. Application of genetics methods and fast diagnosis culture systems significantly improved the laboratory diagnosis compared with the conventional L-J cultures. |
| 80 | FACTORS AFFECTING INCIDENCE OF AND SURVIVAL AFTER CMV END-ORGAN DISEASE IN PATIENTS WITH AIDS IN EUROPE European AIDS Conf 2001 Oct 28-31;8: (abstract no. 80) I Yust1, P Reiss, D Turner1, O Kirk2, C Katlama, A Mocroft, J van Lunzen, M Burke1, A Chiesi, JD Lundgren2 for the EuroSIDA Study Group. The decrease in mortality from CMV infection is associated with several factors, including a decreased incidence of CMVD, as well as improved body weight, higher CD4 cell counts and hemoglobin levels, most of these presumably associated with HAART. Further, the site of CMV infection plays a role: patients with gastrointestinal or retinal involvement alone did better than those with neurologic or other extraocular involvement. |
| 81 | EVOLVING GENOTYPIC RESISTANCE PATTERNS AND LONGTERM DURABILITY OF NEVIRAPINE-BASED REGIMENS IN HAART NAÏVE PATIENTS European AIDS Conf 2001 Oct 28-31;8: (abstract no. 81) H Wheeler1 C Skinner1, M Murphy2, J Norman2, A Chowdury2, C Aitken2 To assess baseline and evolving genotypic resistance patterns in a cohort of antiretroviral naïve patients commenced on nevirapine (NEV) :a long term follow up. |
| 82 | CHEMOKINE mRNA LEVELS IN NATIVE PERIPHERAL BLOOD MONONUCLEATED CELLS OF HIV INFECTED INDIVIDUALS BEFORE AND AFTER INITIATION OF PI VERSUS NNRTI-CONTAINING HAART REGIMENS European AIDS Conf 2001 Oct 28-31;8: (abstract no. 82) Dumoulin FL, Nischalke HD, Wasmuth JC, Jütte A, Fätkenheuer G, Salzberger B, Sauerbruch T, Spengler U, Rockstroh JK The data suggest that HAART regiments containing NNRTI instead of PI are equally effective with regards to modification of chemokine profiles during immune reconstitution. |
| 83 | PHARMACOKINETIC AND PHARMACODYNAMIC CHARACTERISTICS OF EMTRICITABINE SUPPORT ITS ONCE DAILY DOSING European AIDS Conf 2001 Oct 28-31;8: (abstract no. 83) L. Wang, J. Begley, J. Feng, J. Quinn and F. Rousseau Cancelled, abstract not available. |
| 84 | AMPRENAVIR (APV) PLUS LOPINAVIR/RITONAVIR (LPV/r) VERSUS LPV/r AS THE SOLE PI IN SALVAGE ANTIRETROVIRAL (ARV) THERAPY European AIDS Conf 2001 Oct 28-31;8: (abstract no. 84) M. Loutfy, R. Hancock, S. Walmsley In this retrospective cohort study, the combination of APV and LPV/r in salvage therapy had no virologic disadvantage over LPV/r alone. However, a larger sample size would be required to determine if there was a statistically significant difference in the virologic or CD4 response to the combination PI. |
| 85 | IMMUNOLOGICAL COMPONENTS OF HYPERSENSITIVITY TO ABACAVIR European AIDS Conf 2001 Oct 28-31;8: (abstract no. 85) Vyakarnam A.1, King D.1, Tomkins S.1, Easterbrook P.1, Raffi F.2, Thurmond L.3, Thorborn D.3, and M. Kemeny1 The increases in IL4-producing T cells in both the CD4 and CD8 compartments observed in patients who experienced a hypersensitivity reaction indicates a slight shift in the balance of cytokines IFNg (type 1) and IL4 (type 2) which may encourage type 2 immune responses. However, it is unclear at this stage whether the increased IL4 production is a possible causative factor in hypersensitivity. Continuing investigation will help define the precise cellular mechanisms that underlie this adverse drug reaction. |
| 86 | BID FIRSTLINE RITONAVIR/INDINAVIR (RTV/IDV) 100/800 IN A GERMAN MULTICENTER STUDY: 48 WEEK RESULTS European AIDS Conf 2001 Oct 28-31;8: (abstract no. 86) Voigt E ,Wickesberg A, Gute P1, Locher L1, Salzberger B2, Wöhrmann A2, Schröer K P2, Adam A3, Weitner L3, and Rockstroh J K The combination of RTV/IDV 100/800mg bid appears to be effective up to 48 weeks, despite high baseline VL and low CD4 counts in ARV naïve patients. However, discontinuation due to adverse events, especially nephrotoxicity, is frequent and limits treatment duration. Therefore extra hydration appears inevitible. However dosing regimens with lower drug levels should be considered in future treatment concepts and will be examined by the authors‘ group. |
| 87 | STRUCTURED THERPY INTERRUPTION (STI) IN CHILDREN WITH HIV-INFECTION European AIDS Conf 2001 Oct 28-31;8: (abstract no. 87) Vocks-Hauck, M1 Noll, F2 Schmidt, B3 Despite of reduction of the CD4 cell count no child developed clinical symptoms. Side effects of antiretroviral drugs could be avoided by STI. Especially after longer STI`s a reduction of drug resistance was found. All children, adolescents and their parents valued their STI`s positively. Therefore further studies about STI in children are necessary. |
| 88 | CD38 QUANTITATION ON CD8+DR+ AND CD8+DR- T CELLS IN HIV-1(+) INDIVIDUALS: CORRELATION WITH VIRAL LOAD European AIDS Conf 2001 Oct 28-31;8: (abstract no. 88) Vigklis V, Siorenta A, Michailidis Ch, Lelekis M, Boti S, Stephanou I, Gargalianos P. The increase of viral load leads to strong activation of circulating CD8 lymphocytes resulting in increased CD38 ABC expression. The high correlation between viral load and CD38 ABC on CD8 as well as their subpopulations and the high proportion of CD8+ cells and their subpopulations that express more than 12000 CD38 molecules per cell, shows that CD8 T cell activation determined by viral load reflect a separate pathogenic component of HIV-1 disease. |
| 89 | HIV-1 SPECIFIC CYTOTOXIC T LYMPHOCYTES AND PLASMA VIRAL LOAD IN TREATMENT EXPERIENCED HIV-1 INFECTED PATIENTS European AIDS Conf 2001 Oct 28-31;8: (abstract no. 89) Vigklis V., Spiropoulou-Vlachou M., Siorenta A., Stephanou I., Perdios J., Papadimitropoulos M., Boti S., Stavropoulos C., Gargalianos P. The viral replication in patients with higher viral load is probably required to maintain higher frequencies of Ag specific CD8+ T cells. 2) The lower proportion of CD8+ pol+ cells may reflect fewer reverse transcriptase epitopes than gag. |
| 90 | EFFECT OF LOPINAVIR/r CONTAINING HAART REGIMEN ON LYMPHOCYTE SUBPOPULATIONS IN TREATMENT EXPERIENCED HIV-1 INFECTED PATIENTS (PILOT STUDY) European AIDS Conf 2001 Oct 28-31;8: (abstract no. 90) Vigklis V., Lelekis M., Siorenta A., Chini M., Boti S., Michailidis Ch., Gargalianos P. The early increase of “naïve” CD4 seen in GROUP1 is in sharp contrast with GROUP2; were “naïve” CD4 elevation is a later event. More studies are needed to assess whether this finding is a redistribution phenomenon or an early sign of immune reconstitution. |
| 91 | CONTRASTING PREVALENCE OF INFECTION BY HCV GENOTYPE 4 IN CRONIC HEPATITIS C INTRAVENOUS DRUG USERS WITH AND WITHOUT HIV INFECTION European AIDS Conf 2001 Oct 28-31;8: (abstract no. 91) Aguilera A, Losada E (*), Nóvoa S, Prieto E, Gutierrez D, González-Quintela A (*), Fernández-Castroagudín J (**), Prieto A (*) and Regueiro BJ In contrast to previous reports this study also showed a high prevalence of genotype 4 (around 30%) in European IVDUs with HIV infection. This study also confirm that treatment of CHC in HIV-positive IVDUs patients should consider HCV typing before beginning therapy. |
| 92 | A PROSPECTIVE STUDY ON EFFECTS OF AN EMERGENCY MEDICATION KIT FOR HIV POSTEXPOSURE PROPHYLAXIS IN HIV SERODISCORDANT COUPLES European AIDS Conf 2001 Oct 28-31;8: (abstract no. 92) Albrecht D.1, Lorenzen T.2, Graefe K.2, v. Krosigk A.2, Jarke J.3, Stoehr A.2, Plettenberg A.2 The issuing of an emergency kit of antiretroviral drugs in combination with counseling enables HIV-seronegative partners to initiate HIV-PEP without delay while not increasing risk behavior in serodiscordant couples. |
| 94 | HIV AND TUBERCULOSIS – A RETROSPECTIVE STUDY OF 812 CASES (1990-2000) European AIDS Conf 2001 Oct 28-31;8: (abstract no. 94) Aldomiro F, Maltez F, Machado J, Pacheco M H , Rodrigues P, Martins Baptista A, Cardoso O, Garagorri M, Alvarenga J, Serrano A, Neves da Costa J E, Malhado J, Morgado A, Proença R. In our Ward, tuberculosis in all its clinical presentations has been increasing over the last decade, now being over three times as common as it was in 1990, and was the most important opportunistic infection before and after the introduction of HAART. Apart from the increase in the total number of cases diagnosed, we confirmed that the number of cases of extra pulmonary tuberculosis, as well as the number of infections with MDR strains has become increasingly important over the last decade. |
| 95 | ASSESSMENT OF MENTAL HEALTH (MH) AMONG ANTIRETROVIRAL NAÏVE WOMEN LIVING WITH HIV IN ITALY: THE ICONA-BEHEPI STUDY European AIDS Conf 2001 Oct 28-31;8: (abstract no. 95) Aloisi MS, Murri R, Girardi E, Ferrara M, Serraino D, D’Arminio Monforte A, Moroni M , Ippolito G and ICONA-BEHEPY Study Group The identification of potential determinants of poor MH like those that resulted from the present analysis may be useful for planning additional support service for these women. Since this is an ongoing investigation, differences in access to antiretroviral therapies, antidepressive drugs, and clinical outcomes for women with poor MH will be assessed in the future. |
| 96 | HAART-ASSOCIATED CHANGES IN BODY FAT DISTRIBUTION ARE DETECTABLE IN HIV-INFECTED CHILDREN EVEN IN THE ABSENCE OF CLINICAL EVIDENCE OF LIPODYSTROPHY European AIDS Conf 2001 Oct 28-31;8: (abstract no. 96) Alessandra Viganò, Dorella Bricalli, Natascia Sala, Federica Renzetti*, Paola Manzoni*, Angelo Vanzulli#, Paolo Brambilla* Chair of Pediatrics, L. Sacco Hospital, University of Milan, Italy, *Department of Pediatrics, Scientific Institute H S. Raffaele, University of Milan. #Department of Radiology, Ospedale Ca’ Granda, Milan, Italy Increased central fat and peripheral lipoatrophy are distinctive features of all HAART-treated children and they are detectable by DXA even in the absence of signs of LD. Only LD+ show true central obesity. |
| 97 | RELATIONSHIP OF DEPRESSION, NEUROCOGNITIVE IMPAIRMENT AND HAART ADHERENCE European AIDS Conf 2001 Oct 28-31;8: (abstract no. 97) A. Ammassari, A. Antinori, P. Pezzotti, M.S. Aloisi, M.P. Trotta, R. Murri, P. De Longis, L. Ravasio,G. D’Offizi, M. Zaccarelli, C.M. Izzo, S. Nappa, A. d’Arminio Monforte, G. Ippolito, A. W. Wu, F. Starace for the AdICoNA and NeuroICoNA Study Groups In this study conducted in HIV-positive patients receiving HAART and with a relatively high CD4 cell count, a strong relationship between adherence and depression, but no meaningful association with the presence of minor neurocognitive impairment was found. Recognition and treatment of depression could represent an effective intervention to improve HAART adherence in HIV-positive persons |
| 98 | SYMPTOMS AND MEDICATION SIDE EFFECTS AS DETERMINANT OF SELF-REPORTED NON-ADHERENCE TO HAART ARE RELATED TO ANTIRETROVIRAL PLASMA LEVELS European AIDS Conf 2001 Oct 28-31;8: (abstract no. 98) A. Ammassari, R. Murri, P. Pezzotti, M.P. Trotta, R. Hoetelmans, L. Ravasio, P. De Longis, S. Lo Caputo, P. Narciso, S. Pauluzzi, G. Carosi, S. Nappa, P. Piano, C.M. Izzo, M. Lichtner, G. Rezza, G. Ippolito, A. d’Arminio Monforte, A. W. Wu, A. Antinori for the AdICoNA Study Group Patient-reported symptoms and medication side effects, in addition to patient characteristics, medication-related variables and reasons for drug missing, were associated with HAART non-adherence. Preliminary data show that patient-reported symptoms and medication side effects are associated with suboptimal plasmatic concentration of antiretroviral drugs. These results, if confirmed, can be usefull in clinical practice: accurate assessment of patient-reported symptoms could be a strategy to optimise adherence by treating the symptomatology, choosing the most appropriate drug regimen, or eventually delaying treatment initiation. |
| 99 | LACK OF IMMUNOLOGICAL CONTROL OF VIRAL REPLICATION AFTER STRUCTURED TREATMENT INTERRUPTION (STI) IN CHRONIC HIV INFECTION FOLLOWING SUSTAINED SUPPRESSION OF VIREMIA European AIDS Conf 2001 Oct 28-31;8: (abstract no. 99) Jan van Lunzen1, Frahm N1, Altfeld M2, Hoffmann C3, Schmitz J4, Kuroda M4, Walker B2, Stellbrink HJ1 In chronic HIV infection STI leads to a viral rebound which is associated with T cell activation and proliferation. The virological set point level remains unchanged despite the presence of HIV specific CTL. This argues against the notion of an endogenous vaccination after STI in chronically HIV infected patients achieving long term control of viral replication during HAART. |
| 100 | RISE IN HDL-CHOLESTEROL ASSOCIATED WITH NEVIRAPINE-CONTAINING ANTIRETROVIRAL THERAPY IN HIV-1 INFECTED PATIENTS IS SUSTAINED OVER 48 WEEKS OF TREATMENT European AIDS Conf 2001 Oct 28-31;8: (abstract no. 100) M. van der Valk1, J.J.P. Kastelein2, R.L. Murphy3, F. van Leth1, C. Katlama4, A. Horban5, M. Glesby6, G. Behrens7, B. Clotet8, P. Reiss1 on behalf of the Atlantic Study team The previously demonstrated increase of HDL-c in HIV-1 infected patients treated with a combination of stavudine, didanosine and nevirapine, was sustained up to 48 weeks of therapy and is associated with a very favorable lipoprotein profile, known to lead to a reduced CAD risk. |
| 101 | ONCE DAILY INDINAVIR/RITONAVIR IN PATIENTS UNABLE TO ADHERE TO A BID REGIMEN European AIDS Conf 2001 Oct 28-31;8: (abstract no. 101) M.E.van der Ende1, S de Marie1, I.C. Gyssens1, P.W.H. Hugen2, D.M. Burger2 This study shows that a once daily regimen of indinavir/ritonavir produces adequate steady-state indinavir plasma levels and is well tolerated. Virological and immunological responses were good, considering the very difficult patients. |
| 102 | SPECTRUM OF MORTALITY IN HIV PATIENTS IN THE HAART ERA: ANALYSIS OF 128 DEATHS DURING 1996-2000 IN SPAIN European AIDS Conf 2001 Oct 28-31;8: (abstract no. 102) Valencia ME, Ortega G, Martín-Carbonero L, Soriano V, Moreno V and González Lahoz J. A retrospective analysis of 128 deaths that occurred during the last 5 years demonstrates a progressive decrease in the number of deaths, attributable to end-stage AIDS and AIDS-related diseases. In Spain, tuberculosis is still a very important cause of mortality, and chronic liver disease would be a problem in the future. |
| 103 | AVASCULAR OSTEONECROSIS IN HIV INFECTED PATIENTS RECEIVING HAART: STUDY OF SEVEN CASES European AIDS Conf 2001 Oct 28-31;8: (abstract no. 103) Valencia ME, Ortega G, Moreno V, Soriano V, Blanco F and González Lahoz J. Avascular osteonecrosis may produce joint pain in HIV infected patients, being multifactorial its etiology although protease inhibitors are probably related with its development. Although evolution may be unfavorable, a change in the antiretroviral treatment could improve it. |
| 104 | TUBERCULOSIS AND HIV-COINFECTION: HOW USEFUL IS SMEAR MICROSCOPY TO DIAGNOSE TUBERCULOSIS AND PREVENT FURTHER TRANSMISSION European AIDS Conf 2001 Oct 28-31;8: (abstract no. 104) E. Valadas, S. Gouveia, A. dos Santos, C. Ribeiro, T. Hänscheid*, F. Antunes. Smear microscopy remains a simple and rapid method to diagnose TB and institute imediate treatment and isolation. However, we found that in our patients with pulmonary TB, that may pose a significant infectious risk to others, only half had a positive smear result. Considering the high number of MDR-TB cases (we saw 13 patients in 2000) a high degree of clinical suspicion and imediate isolation until confirmation or exclusion of TB are of great importance. This may even be more important in HIV infected patients, in whom clinical presentation is often subtle. Appropriate isolation facilities for TB and TB suspected cases, specially in settings with a high HIV prevalence, are much needed in order to prevent nosocomial TB. |
| 105 | MULTI-DRUG-RESISTANT TUBERCULOSIS: IS NOSOCOMIAL TUBERCULOSIS A MAJOR PROBLEM IN A DEPARTMENT OF INFECTIOUS DISEASES? European AIDS Conf 2001 Oct 28-31;8: (abstract no. 105) E. Valadas, C. Constant, P. Bravo Ferreira, R. Badura, M.J. Aleixo, L. Caldeira, M. Viveiros∞, L. Brum#, T. Hänscheid*, F. Antunes The large increase in MDR-TB in our Department is of great concern. The clustering of identical resistance patterns suggest transmission of TB from a single source patient that may well have occurred in a nosocomial context. Traditional tuberculosis control measures seem to be insufficient in settings were prevalence of HIV infection and tuberculosis are high. This becomes even more important when the incidence of intravenous substance abuse, and often non-compliance, are predominant factors. Appropriate isolation facilities for all suspected tuberculosis cases as well as rapid diagnostic and drug susceptibility tests will be required to prevent further spread of MDR-TB. |
| 106 | CRYPTOSPORIDIOSIS IN HIV/AIDS PATIENTS BEFORE AND AFTER INTRODUCTION OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY European AIDS Conf 2001 Oct 28-31;8: (abstract no. 106) K. Tzanetou,1 I. Stefanou,2 E. Dolapsaki,1 I. Perdios,2 E. Sambatakou,2 M. Chini,2 A. Strouza,1 E. Kafkoula,1 E. Michaelidou,1 M. Lelekis,2 P. Gargalianos,2 E. Malamou-Lada1 The incidence of cryptosporidiosis before and after HAART period was found to be 10% and 3.6% respectively (not statistically significant difference). The severity and duration of diarrhoea is clearly associated with the CD4 lymphocyte count (severe diarrhoeal syndrome was correlated with CD4 lymphocyte count <100 and <50/ìl, while mild diarrhoeal syndrome with CD4 lymphocyte count >500/ìl). The dramatic decrease of the viral load, even with small or no increase of the CD4 lymphocyte count, after HAART, results in eradication of Cryptosporidium oocysts and diarrhoea resolution without administration of any antimicrobial therapy. (4) The best prevention and treatment of cryptosporidiosis in HIV-1 infected patients is achieved by HAART. |
| 107 | DETECTION OF MICOBACTERIUM TUBERCULOSIS-DNA BY PCR IN CEREBROSPINAL FLUID (CSF): A USEFUL TOOL FOR THERAPEUTIC CHOICES European AIDS Conf 2001 Oct 28-31;8: (abstract no. 107) Garberi J., Serebrinsky S.,Pascucelli V.,Scharlat A.,Coviello S., Ferro F.*,Paz S.**,Troncoso A** These preliminary results strongly suggest that the TB2 assay yield excellent predictive positive and negative values for diagnosis of tuberculosis encephalitis. More over, it is also suggested by the accuracy shown by these results that they might be helpful to exclude M. tuberculosis from infections caused by NTP. Finally, we rule out the utilization of TB1 assay for the early detection of M. tuberculosis in CSF samples due to its low sensitivity. |
| 108 | RHODOCOCCUS EQUI (RE) INFECTION SIMULATING PULMONARY TUBERCULOSIS European AIDS Conf 2001 Oct 28-31;8: (abstract no. 108) Mendez N., Caminada F., Gulotta H.*, Giorgi L., Papagno M., Laciar M., Echazarreta B., Troncoso A* Factors for delayed diagnosis include the insidious onset of disease, clinical resemblance of the infection to mycobacterial, fungal, and actinomycotic infections, and the relatively nondescript bacteriologic profile of RE. Morphology, partial acid fastness, and a distinctive histopathologic profile in bronchial specimens contribute to accurate diagnosis. The definitive diagnosis require isolation and identification of RE from bronchial washings, sputum, open-lung biopsy, blood cultures. Intra and extracellular bacterial populations should be covered in the antibiotic induction treatment (vancomycin or imipenem plus erythromycin and rifampin). |
| 109 | ANNUAL PREVALENCE OF CRYPTOSPORIDIUM AMONG AIDS PATIENTS European AIDS Conf 2001 Oct 28-31;8: (abstract no. 109) Bava Javier, Cattáneo Sylvia, Bellegarde Enrique, Alcides Troncoso-Uspallata The prevalence of Cryptosporidium in AIDS patients with diarrhea seems not to be significantly influenced by the climatic factors in the studied population. The introduction since 1998 of HAART seems to be producing a decrease of the prevalence of Cryptosporidium. |
| 110 | ANALYSIS OF LONGITUDINAL T-CELL EXCISION DNA LEVELS IN HIV-1 INFECTED SUBJECTS PRE AND POST-HAART European AIDS Conf 2001 Oct 28-31;8: (abstract no. 110) G. Touloumi1, R. Karanicolas2, N. Pantazis1, A. Karafoulidou3, T. Mandalaki3, J.J Goedert4, L. G. Kostrikis2, A. Hatzakis1 While TREC values may not be a direct indicator of thymic output, our results show that TREC’s represent a simple indicator of naïve T-lymphocyte reserve and may be a clinically useful marker for long-term prognosis of HIV-1 infection and of immune reconstitution after successful HAART. |
| 111 | INSULIN ACTION IS CORRELATED TO FAT DISTRIBUTION AND GLYCOGEN SYNTHESIS MAY BE IMPAIRED IN HIV ASSOCIATED LIPODYSTROPHY SYNDROME European AIDS Conf 2001 Oct 28-31;8: (abstract no. 111) Ove Andersen, Steen B Haugaard, Ulrik Andersen, Heidi Storgaard, Finn Somnier, Johan Iversen & Sten Madsbad These results provide evidence suggesting that male HALS patients do exhibit a lower level of non-oxidative glucose metabolism (a marker of glycogen synthesis in muscular tissue), however do not exhibit any sign of disordered oxidative glucose metabolism when compared to controls. Furthermore, the finding of a correlation between the percentage of limb fat and the insulin sensitivity suggests that the redistribution of adipose tissue may be of importance to the reduced action of insulin in HALS patients. |
| 112 | COMPLETE REGRESS OF ELEVATED CEREBROSPINAL FLUID NEUROFILAMENT PROTEIN LEVELS AFTER INITIATION OF INDINAVIR, LOW-DOSE RITONAVIR, LAMIVUDINE AND ZIDOVUDINE IN A PATIENT WITH HIV-1 ASSOCIATED DEMENTIA European AIDS Conf 2001 Oct 28-31;8: (abstract no. 112) Andersson LM, Hagberg L, and Gisslén M In this patient the regimen used was effective in reversing clinical symtoms and normalizing CSF NFp levels. NFp is a promising marker for monitoring of antiretroviral treatment response in HIV-1 associated dementia. |
| 113 | HIV-HCV COINFECTION: EVOLUTION OF LIVER DISEASE AND POSSIBILITIES OF LIVER TRANSPLANTATION European AIDS Conf 2001 Oct 28-31;8: (abstract no. 113) M. Torralba, G. Palao, A. Díaz de Tuesta, J. Olalla, A. Costa, JR. Costa, R. Rubio The prevalence of HIV-HCV coinfection and the number of patients with elevated serum ALT/AST are high. In our institution, ESLD is relatively frequent and makes antirretroviral therapy a hazardous one. |
| 114 | ENTEROVIRUS INFECTIONS OF THE CENTRAL NERVOUS SYSTEM IN HIV-INFECTED PATIENTS: A NEW SPECTRUM OF DISEASE European AIDS Conf 2001 Oct 28-31;8: (abstract no. 114) Thomson GL, Punter M, Bailey A, Klapper PE, Bonington A Although HIV infection has not previously been reported as a risk factor for enterovirus infection of the CNS, this study demonstrates that this occurs relatively frequently. Furthermore, this study suggests that in the setting of HIV-related immunosuppression, enteroviruses may produce a previously unrecognised spectrum of disease that includes encephalopathy, peripheral neuropathy and PML-like disease. With the development of anti-retroviral agents such as pleconaril, the rapid and accurate diagnosis of enteroviral infections will assume greater importance |
| 115 | KALETRA (LOPINAVIR/RITONAVIR) IN ANTIRETROVIRAL-NAÏVE HIV+ PATIENTS: 3 YEAR FOLLOW UP European AIDS Conf 2001 Oct 28-31;8: (abstract no. 115) M Thompson, S Brun, M King, B Richards, R Murphy, R Gulick, M Glesby, C Hicks, R Stryker, J Eron, C White, C Benson, H Kessler, M Albrecht, T Marsh, E Sun Kaletra-based therapy demonstrated antiviral activity and was generally well tolerated in ARV-naïve patients through 3 years of follow-up. |
| 116 | LONG-TERM EVALUATION OF VIROLOGICAL RESPONSE TO SALVAGE THERAPY AFTER GENOTYPING RESISTANCE TEST IN AN UNSELECTED COHORT European AIDS Conf 2001 Oct 28-31;8: (abstract no. 116) Perno CF, Girardi E, Trotta MP, D’Arrigo R, Zaccarelli M, Bellocchi MC, Liuzzi G, P Narciso, P De Longis, A Bertoli, V Tozzi, G D’Offizi, G Ippolito, A Antinori In an unselected cohort multiple failed patients a GRT-based strategy of salvage therapy allow to obtain a high probability of virological suppression during time. Magnitude of virological response before GRT, NNRTI-naïve status and use of NNRTI-containing salvage regimens, selected resistance-conferring mutations and number of active drugs based on genotyping results, were all predictive of response to salvage therapy. |
| 117 | MAGNETIZATION TRANSFER IMAGING IN HIV-1-RELATED CEREBRAL WHITE MATTER LESIONS. CORRELATION WITH VIROLOGICAL BURDEN IN CEREBROSPINAL FLUID European AIDS Conf 2001 Oct 28-31;8: (abstract no. 117) A Antinori, ML Giancola, E Busi Rizzi, S Grisetti, A Di Caro, V Schininà, AM Bellussi, A De Santis, M Capobianchi, G Ippolito, C Bibbolino MTR was lower in PML than HIV encephalopathy as well as in positive or negative JCV-DNA. FU. Magnetization transfer MR imaging is a useful method to distinguish PML from HIV encephalopathy even when the detection of JCV-DNA results negative. Correlation with level of CSF HIV-1 replication suggests a possible role of MTR according with HIVE severity. |
| 118 | CHANGING PATERNS IN HIV-1 RELATED NEUROLOGICAL DISORDERS DURING HAART ERA. DATA FROM THE ITALIAN REGISTRY INVESTIGATIVE NEURO AIDS (IRINA) European AIDS Conf 2001 Oct 28-31;8: (abstract no. 118) A Antinori, A Ammassari, P Cinque, F Soldani, P Lorenzini, L Toma, A Govoni, ML Giancola, A d’Arminio Monforte, S Grisetti, C Pierotti, A Cingolani, MG Finazzi, T Bini, V Tozzi, C Fausti, L Cristiano, S Foresti, G Guaraldi, L Monno, B Vigo, G Mazzarello, M Gentile, M Mena, MI Arcidiacono, G Fasulo, G Rezza, G. Ippolito More than half of neurologic disorders observed in the last year of HAART impact occur in patients treated with antiretrovirals, even if most of them experienced virological failure and immunologic impairment. Prevalence of HIV-1-related neurolgic diseases substantially differ from that observed before HAART introduction. A clear reduction of HIVE and PCNSL was observed, whereas an increasing prevalence rate of PML was registered and TE remained the most prevalent picture in naive as well as in HAART-treated patients. CD4 count and HIV-1 RNA at diagnosis discriminate several specific CNS disorders, probably according to different HAART effect on disease activity. Emerging picture of white matter leukoencephalopathy occurred particularly in female and in patients with low level viremia and CD4 immunorecovery. |
| 119 | PROLONGED SURVIVAL IN AIDS-RELATED PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA TREATED WITH HAART European AIDS Conf 2001 Oct 28-31;8: (abstract no. 119) A Antinori1, S Bossolasco2, A Cingolani3, L Alba1, B Ciancio3, D Serraino1, A Lazzarin2, LM Larocca4, and P Cinque2 HAART, especially if initiated after PCNSL diagnosis, increased survival probability of AIDS-PCNSL even adjusting for PCNSL treatment and response. Long-term survival is associated with viro-immunological response. |
| 120 | MORTALITY BETWEEN HIV PATIENTS IN THE HAART ERA European AIDS Conf 2001 Oct 28-31;8: (abstract no. 120) Cubo P, Téllez MJ, González-Castillo J, Muñoz S, Roca V, Fernández-Cruz A. We observe a progressive decrease of mortality. Nevertheless, it has remained stable in the last 3 years. The improvement of the immunologic situation of the HIV patient has caused a decrease in opportunistic infections mortality. The chronic diseases have become a problem in these patients. In the present study, the chronic hepatopathy is the first cause of mortality. |
| 121 | CEREBRAL AND CARDIAC STROKES IN HIV PATIENTS European AIDS Conf 2001 Oct 28-31;8: (abstract no. 121) González-Castillo J, Herreros B, Sopelana D, Cuenca R, Téllez MJ, Fernández-Cruz A The incidence of this type of events in VIH+ population is, in our experience, superior to young general population (9 cases/100.000 habitants-year). These episodes might cause by peripheral vasculopathy associated with the HIV infection, increasing the risk in presence of drugs abused and nicotine consume. The IP's wide use does not seem to have provoked up an important effect in the incidence of vascular events at this moment. Though it is necessary to treat vigorously the lipid disorders, as well as the rest of cardiovascular risks. |
| 122 | MORTALITY DUE TO HEPATOPATHY IN HIV PATIENTS European AIDS Conf 2001 Oct 28-31;8: (abstract no. 122) Muñoz S, González-Castillo J, Téllez MJ, Cubo P, Roca V, Fernández-Cruz A Mortality due to chronic hepatopathy has increased in last years representing now, in our experience, the mean cause of death in HIV patients. Probably, alcohol has contributed to early development of liver disease in these patients. We also noticed a high prevalence of HBV and HCV co-infection. |
| 124 | ANTI-HIV THERAPY IN PREGNANT WOMEN. EVALUATION OF SHORT-TERM EFFECTS ON MOTHER-BABY PAIR. EXPERIENCE AT POLICLINICO “A. GEMELLI”, ROME European AIDS Conf 2001 Oct 28-31;8: (abstract no. 124) E. Visconti, L. Pastore Celentano, S. Marinaci, P. Villa, G. Oliva, C. Fundarò, O. Genovese, E. Tamburrini A highly effective anti-HIV therapy should be offered to all HIV positive pregnant women in order to prevent vertical transmission, without (or with minor) side effects on the newborn. In consideration of the increasing number of HIV infected women treated with PIs, this protocol could be reliably used in HIV pregnant women, in order to have the “best” treatment of the mother too. |
| 125 | HIV-1 DYNAMICS IN VIVO AND ANTIVIRAL EFFICACY OF PEGYLATED INTERFERON-α-2b European AIDS Conf 2001 Oct 28-31;8: (abstract no. 125) V. Sypsa, M. Laughlin, P. Gargalianos, M. Lazanas, C. Botsi5, G. Saroglou, C. Anastassopoulou1, H. Sabatakou, N. Magafas, N. Stavrianeas, P. Giannakopoulou, A. Hatzakis The observed viral decline after PEG-INTRON administration is biphasic, as shown for HCV, Dose has a significant effect on antiviral efficacy, The positive association of baseline CD4 with antiviral efficacy indicates that patients with relatively intact cell-mediated immunity are more responsive to PEG-INTRON monotherapy, and The dose of 3.0 µg/kg yielded the greatest antiviral suppressive effect but further clinical evaluation is required to determine the optimal long-term dose. |
| 126 | GENOTYPIC RESISTANCE PROFILE AMONG PATIENTS UNDER HAART AND UNDETECTABLE VIRAL LOAD European AIDS Conf 2001 Oct 28-31;8: (abstract no. 126) Sucupira M.C.A., Silva W.P., Acceturi C.A., Turcato G., Lewi D.S., Diaz R.S. We detected a high level of genotypic resistance mutations among patients under HAART and undetectable viral load. The prevalence of NNRTI resistance related mutations was higher in these set patients of patients than in what is usually found in primary resistance surveys in our country. We hypothesis that this might be due to the selective pressure of ARVS of other class. The use of proviral HIV-1 genotyping in patients under HAART and undetectable viral load may be a tool for close virologic monitoring, therefore helping to prevent viral rebound before it occurs. |
| 127 | SALVAGE TREATMENT WITH LOPINAVIR/RITONAVIR (KALETRA) IN HIV-INFECTED PATIENTS FAILING ALL CURRENT ANTIRETROVIRAL DRUG FAMILIES European AIDS Conf 2001 Oct 28-31;8: (abstract no. 127) Carmen de Mendoza, Luz Martín-Carbonero, Pablo Barreiro, Beatriz Díaz, Eulalia Valencia, Inmaculada Jiménez-Nácher*, Marina Núñez, Oscar Gallego, Juan González-Lahoz and Vincent Soriano Kaletra™ is relatively well tolerated and provides a potent antiviral activity in heavily pre-treated subjects. Plasma HIV-RNA reductions >1 log are seen in nearly three quarters of patients. Genotyping at the time of beginning salvage therapy with Kaletra might help to predict which individuals will experience a greater benefit. |
| 128 | MATERNAL CHARACTERISTICS OF HIV-INFECTED WOMEN IN A PROSPECTIVE SURVEY OF ANTIRETROVIRAL TREATMENT DURING PREGNANCY AND MATERNAL AND NEONATAL EFFECTS. PRELIMINARY RESULTS European AIDS Conf 2001 Oct 28-31;8: (abstract no. 128) Solis I In our cohort of HIV-infected mothers, most were asymptomatic during pregnancy. Drug use is the main risk factor for infection, although heterosexual transmission is increasing. Common associated medical conditions are hepatitis C virus coinfection and gestational diabetes. In spite of highly active antirretroviral treatment and low plasma viral load at delivery there is a large proportion of elective cesarean section. The tolerance to AR during pregnancy appears to be good. |
| 129 | TENOFOVIR DF: AN ANALYSIS OF THE OPEN LABEL EXTENSION PHASE FROM A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY IN ANTIRETROVIRAL EXPERIENCED PATIENTS European AIDS Conf 2001 Oct 28-31;8: (abstract no. 129) G. Skowron1, J. Nadler2, M. Thompson3, T. Schacker4, S. Jacobson5, C. Cohen6, S.S. Chen7, N. Margot7, M.D. Miller7, E. Isaacson7 and A. Cheng7 for the Study 902 Team. At nearly 2 years, once daily tenofovir DF 300 mg is well tolerated and provides continued antiviral activity in treatment experienced patients with high levels of nucleoside resistance. The emergence of resistance to tenofovir DF occurred infrequently. |
| 130 | CIRCULATING SOLUBLE CD40 LIGAND LEVELS CORRELATE WITH CD4 + T CELL COUNTS IN HIV-1 INFECTED PATIENTS European AIDS Conf 2001 Oct 28-31;8: (abstract no. 130) Nikolaos V. Sipsas, Petros P. Sfikakis, Athanasios Kontos, Theodore Kordossis In HIV-1 infection, the progressive decline of CD4+ T cell counts is followed by a decline in sCD40L serum levels, since CD40L is expressed mainly on CD4+ T cells. sCD40L levels reflect specifically the numbers of activated CD4+ T cells and not the immune activation in general. The increase in CD4+ T cell counts, due to HAART induced viral suppression, is followed by a similar increase of serum sCD40L levels. In conclusion, our data suggest that sCD40L levels could be a useful surrogate marker in HIV-1 infection. |
| 131 | MIXED CRYOGLOBULINEMIA IS ASSOCIATED WITH INCREASED RISK FOR DEATH OR NEOPLASIA IN HIV-1 INFECTED PATIENTS European AIDS Conf 2001 Oct 28-31;8: (abstract no. 131) Theodore Kordossis, Nikolaos V. Sipsas, Athanasios Kontos, *Urania Dafni, Haralampos M. Moutsopoulos Our results suggest that cryoglobulinemia is associated with an increased risk for death, neoplasia or development of lymphoproliferative disorder of B-cell origin, in HIV-1 infected patients. |
| 132 | PERFORMANCE OF NUCLISENS HIV-1 QT, A SENSITIVE HIV VIRAL LOAD ASSAY, IN A MULTI-CENTER TRIAL European AIDS Conf 2001 Oct 28-31;8: (abstract no. 132) F. Simons, D. Witt, M. Kemper, K. Stellrecht, C. Ginocchio The NucliSens HIV-1 QT demonstrated a excellent sensitivity and was highly specific with a broader linear dynamic range compared to other amplification assays for HIV-1 RNA. |
| 133 | NO INFLUENCE OF EXERCISE ON HIV-1 VIRAL LOAD European AIDS Conf 2001 Oct 28-31;8: (abstract no. 133) P. Simons, G. Muyldermans, P. Lacor, K. De Meirleir We conclude that acute exercise is safe in people with HIV-1 infection because it does not increase HIV-1 viral load. These data are relevant in the perspective of future exercise strategies for the management of HAART-associated hyperlipidemia and lipodystrophy. |
| 134 | NON OCCUPATIONAL POST EXPOSURE PROPHYLAXIS (NONOPEP) FOR HIV IN EUROPE: REVIEW OF POLICIES AND IMPLEMENTATION OF AN EUROPEAN REGISTRY European AIDS Conf 2001 Oct 28-31;8: (abstract no. 134) J. Almeda, J. Casabona, B. G. Simon, and for the NONOPEP Working Group: E. Bernasconi, M. Gerard A. Mota Miranda, V. Puro, D. Rey, G. Sonder, J.Tomazic In the majority of the european countries, there are neither national guidelines nor national registry on NONOPEP. The number not negligible of cases already collected by the existing registries, confirm that the demand of NONOPEP is indisputable. The risk evaluation, the indication and the type of treatment are very variable. The question about the effectiveness, the feasability and the european standardization of the policies of the non occupational post exposure prophylaxis for HIV is still a topical question and justifies the need of an European Registry to collect and analyse the data of the patients who consult for a NONOPEP. |
| 136 | REASONS FOR REFUSING INFERTILITY TREATMENT TO HIV INFECTED PATIENTS European AIDS Conf 2001 Oct 28-31;8: (abstract no. 136) Ade Apoola, J tenHof, PS Allan It is possible to debunk all of the reasons given as to why infertility investigations and treatment is not offered to HIV infected patients as long as universal testing of all patients investigated or treated in the clinic is not carried out. |
| 137 | AMPRENAVIR (APV) 600mg/ RITONAVIR (RTV) 100mg BID or APV 1200mg/RTV 200mg QD GIVEN IN COMBINATION WITH ABACAVIR (ABC) AND LAMIVUDINE (3TC) MAINTAINS EFFICACY IN ART NAÏVE HIV-1 INFECTED ADULTS OVER 24-wEEKS (APV20001) European AIDS Conf 2001 Oct 28-31;8: (abstract no. 137) K Arasteh1, R Wood2, E Teofilo3, F Raffi4, J Eron5, P Kaur6, O Naderer7, A Butler6 Switching APV 1200mg BID to APV 600mg/RTV 100mg or APV 1200mg/RTV 200mg QD allows reduction of the total daily pill count of APV (from 16 to 8 capsules daily) with maintenance of virologic suppression and minimal safety issues. |
| 138 | STUDIES ON HOST GENOTYPES AND DISEASE PROGRESSION IN HIV-1 INFECTED BULGARIAN INDIVIDUALS European AIDS Conf 2001 Oct 28-31;8: (abstract no. 138) Savov, A.1, Argirova, R.2, Kremensky, I.1, Rachev, P.3, Froloshka,L.2, Raleva, S.2, Markova, R.4, Terzieva V.4 The results obtained in our study are not sufficient to confirm unequivocally the role of genetic polymorphism of CCR5, CCR2 and SDF-1 genes in different combinations for the course of HIV-1 infection and for genetically determined response to antiviral therapy. |
| 139 | EFAVIRENZ-ASSOCIATED LIVER TOXICITY: A PROSPECTIVE COHORT STUDY European AIDS Conf 2001 Oct 28-31;8: (abstract no. 139) Juan A. Arnaiz1, Esteban Martinez2, Anna Cruceta2, Jose B. Perez-Cuevas2, Ana Milinkovic2, Elisa de Lazzari3, Jose M. Gatell2 Hepatotoxicity defined as an at least 5-fold increase of aminotransferases above the ULN was uncommon in HIV-1-infected patients receiving efavirenz-containing regimens and its incidence remained stable over time. No cases of clinical hepatitis appeared during the follow-up period. |
| 140 | EFFICACY AND SAFETY OF SWITCHING TO EFAVIRENZ FROM PI BASED THERAPY IN PATIENTS WITH PI RELATED ADVERSE EVENTS European AIDS Conf 2001 Oct 28-31;8: (abstract no. 140) Sighinolfi Laura, Roda Rinaldo, Carradori Silvia, Ghinelli Florio These data suggest that switching from PI to EFV is associated with an improvement of HAART tolerability, a decrease in gliycemia and triglycerides in patients with PI –related adverse clinical events. Effectiveness of switching on lipodystrophy is not clear. Viral suppression and CD4 levels are conserved at 9 month and in some patients are sustained at 12 month. Early switching from PI to EFV is safe and effective and can be considered as first option for treatment of PI related adverse events in patients with good virologic and immunologic response to HAART. |
| 142 | RARE CLINICAL MANIFESTATIONS OF CMV-INFECTION IN HIV-INFECTED PATIENTS European AIDS Conf 2001 Oct 28-31;8: (abstract no. 142) V.I. Shakhgildian, A.V. Kravtchenko, O.A.Tishkevitch, P.G. Filipov HIV-infected patients who fail to promptly apply for medical assistance, or who receive inefficient of HAART treatment despite frequently registered clinical manifestations of CMV-infection, develop rare manifestations of this disease. The diagnostics of rare forms of CMV-disease during lifetime of the patient is of great importance for timely beginning of etiotropic therapy. |
| 143 | TUBERCULOSIS IN PORTUGUESE AIDS PATIENTS European AIDS Conf 2001 Oct 28-31;8: (abstract no. 143) Serrão MR, Gomes MH, Ribeiro N, Lima-Alves C, Abreu C, Marques R, Mota-Miranda A. We emphasise the importance of TB and HIV co-infection. MDR-Mt has not been frequently detected, in spite of the large number of IVDU’s pts and their usual non-adherence to therapy. |
| 144 | ANTIRETROVIRAL THERAPY IN A COHORT OF HIV-2 INFECTED INDIVIDUALS IN THE NETHERLANDS European AIDS Conf 2001 Oct 28-31;8: (abstract no. 144) M.E. van der Ende, K. Brinkman, J.M. Prins, M. Keuter, S.A. Danner, H.G.M. Niesters, A.D.M.E. Osterhaus, M. Schutten As a result of the limited availability of effective antiretroviral drugs, succesful treatment of HIV-2 infected individuals will rely on the first line regimen even more then it does in HIV-1 infection. On basis of the data presented we propose as prefered first line therapy AZT, 3TC with IDV or IDV+RTV. |
| 145 | HIV-1 SUBTYPE DETERMINATION IN ROUTINE CLINICAL SAMPLES FROM 5 COUNTRIES USING AN INTERNET-BASED SUBTYPING TOOL European AIDS Conf 2001 Oct 28-31;8: (abstract no. 145) . Boulmé, O. Dugas, I. Robert, R. Hemmer, V. Arendt, T. Staub, B. Schmidt, H. Walter, K. Korn, P. Halfon, N. Clumeck, P. Hermans, S. Dewit, R. Diaz, J.C. Schmit HIV-1 subtype determinations starting from sequences obtained in the clinical resistance genotyping routine are feasible with easy-to-use internet-based tools, thus allowing to create simple surveillance systems for subtype distributions in most countries. The prevalence of subtypes vary largely from one country to another, even in Europe. However, these results are influenced by the patient material submitted for genotyping (patient selection) and the primers for amplification and sequencing which may not equally detect all subtypes. In addition, internet-based subtyping tools do not always correctly recognize recombinants others than the common CRFs. |
| 146 | SAFETY AND EFFECTIVENESS OF NEVIRAPINE-CONTAINING REGIMENS IN HIV-INFECTED CHILDREN European AIDS Conf 2001 Oct 28-31;8: (abstract no. 146) Sanz FJ, Ramos JT, De Jose MI, Fortuny C, González Montero R, Navarro ML, Roa MA, Bosque M, Ciria L, Mur A, Villota J NVP in combination with PI might be effective as salvage therapy in pretreated children. NVP as part of a quadruple regimen is well tolerated and highly effective in infants. Our data are in keeping with previous studies that suggest that higher doses of NVP should be used in children to obtain a more potent and durable antiviral effect. |
| 147 | USEFULNESS OF RESISTANCE ASSAYS BEFORE SALVAGE THERAPY IN HIV-INFECTION. RESULTS AT 6 MONTHS European AIDS Conf 2001 Oct 28-31;8: (abstract no. 147) I. Santos, J. Sanz, C. Sánchez, I. Fuentes, R. Carrillo, C. Jiménez The resistance assay is a very useful tool to guide the salvage therapy in heavily treated patients, as demonstrated to achieve 50% of patients with viral load below limit of detection at three months and a median decrease of 1.5 log in the baseline viral load. |
| 148 | EFFICACY OF NELFINAVIR (NFV) AS SALVAGE THERAPY FOR PROTEASE INHIBITORS (PI) FAILURES European AIDS Conf 2001 Oct 28-31;8: (abstract no. 148) Santos J, Palacios R, Ruiz I, Carmona A, Gordillo MV, Knobel H, Casado JL, González J, García JJ, Traseira S NFV may be a good option as a rescue therapy after other PI failures. The mean increase in CD4 cells among adherent pts was near 100 cells/µl and almost 50% of them reached undetectable VL at month 12. SQV-experienced pts had the best response and disease progression was more frequent in IDV-SQV experienced ones. Adverse effects were rare. |
| 149 | COMPARATIVE ANALYSIS OF THE EFFECT OF PNEUMOCOCCAL VACCINATION ON HIV REPLICATION AND CD4 LYMPHOCYTE COUNT IN ASYMPTOMATIC AND NAÏVE HIV-PATIENTS European AIDS Conf 2001 Oct 28-31;8: (abstract no. 149) J. Santos, R. Palacios, I. Viciana, J. Ruiz, M. González, E. Clavijo, M. Márquez Pneumococcal vaccine doesn’t lead to any variation in plasma VL and CD4 lymphocyte count in asymptomatic and naïve HIV patients. |
| 150 | TWO RANDOMIZED, CONTROLLED, EQUIVALENCE TRIALS OF EMTRICITABINE (FTC) TO LAMIVUDINE (3TC) European AIDS Conf 2001 Oct 28-31;8: (abstract no. 150) I. Sanne1, C. van der Horst2, A. Shaw3, C. Wakeford3, J. Hinkle3, J. Quinn3 and F. Rousseau3 on behalf of the FTC-303/302 Clinical Investigators Abstract withdrawn |
| 151 | CHANGING PATTERNS IN MOTHER TO CHILD TRANSMISSION OF HIV-1 European AIDS Conf 2001 Oct 28-31;8: (abstract no. 151) Emilia Sánchez1, Claudia Fortuny2, Montse Lonca3, Josep M Boguñà2, Oriol Coll3, Rafael Jiménez2 Implementation of prophylactic measures has progressively reduced VTR to the “almost zero” value. After October 1994, no infant delivered by ECS became infected. Availability of antiretroviral therapies and successful preventive strategies seem to favor pregnancies among HIV-1 infected women (observed increase in the number of births and also in the mother’s mean age at delivery). |
| 152 | SPLENIC TUBERCULOSIS IN PATIENTS INFECTED WITH HUMAN IMMUNODEFICIENCY VIRUS – A REPORT OF 18 CASES European AIDS Conf 2001 Oct 28-31;8: (abstract no. 152) C. Salvado, S. Braz, J. Machado, F. Maltez, Morgado, R. In this series the tuberculosis splenic abscesses were present exclusively in DTB, in patients severely immunocompromised and mainly in IVDU. The splenic envolvement was not a rare event and a ultrasonographical study must be included in the evaluation of the HIV and TB patient. The clinical outcome with medical therapy was favorable and the mortality rate appeared to be due to progression of HIV infection rather than TB. |
| 153 | COMPARISON OF EFFICACY AND SAFETY OF AMPRENAVIR (APV) VERSUS APV/RITONAVIR (RTV) IN HIV-1 INFECTED ANTIRETROVIRAL THERAPY (ART) EXPERIENCED ADULTS. - 8 WEEKS ANALYSIS : PROF3020, AGIR STUDY European AIDS Conf 2001 Oct 28-31;8: (abstract no. 153) D. Salmon, M. Garré, D. Jeantils, C. Katlama, C. Michelet, A. Goetschel, JM Vauthier Antiviral efficacy was similar in both groups at week 8. However, viral suppression was more rapid in subjects treated with APV+RTV than those treated with APV alone. The latter regimen may lead to improved adherence with a decreased pill burden. These interesting results need to be confirmed in by larger trials. |
| 154 | PREVALENCE OF METABOLIC "SYNDROME X" IN A COHORT OF HIV PATIENTS TREATED WITH HAART European AIDS Conf 2001 Oct 28-31;8: (abstract no. 154) P. Sacchi1, C. Gazzaruso3, R. Bruno1, R. Maserati2, C. Zocchetti1, E. Seminari2, SFA Patruno1, G. Filice1 Metabolic "Syndrome X" has a prevalence in this cohort of patients higher than that expected in a population of non HIV subject with comparable age and sex distribution. This finding seems to confirm previous observations regarding the increased cardiovascular risk in HIV patients. Associated factor might be the time of exposition to protease inhibitors. |
| 155 | CLINICAL EXPERIENCE OF AMPRENAVIR IN TREATMENT EXPERIENCED PATIENTS IN THE UK European AIDS Conf 2001 Oct 28-31;8: (abstract no. 155) Deenan Pillay, Caroline Sabin Given the highly experienced nature of these patients, the response to APV was good and the drug was reasonably well tolerated. Baseline measures of resistance were strongly predictive of the response to therapy, independently of the baseline viral load and the number of drugs previously exposed to, suggesting that there is value in obtaining resistance measurements in addition to a good treatment history. |
| 156 | INCREASED INTRACELLULAR IL-4 AND APOPTOSIS IN T CELLS CORRELATES WITH CD8CD38 EXPRESSION DURING HIV INFECTION European AIDS Conf 2001 Oct 28-31;8: (abstract no. 156) Maria Jorge Arroz, Diane Ordway, Mónica Freire, Leonor Costa, Fernando Ventura Increased T cell IL-4 production and apoptosis during HIV infection correlates (Spearman test, R=0.665, IL-4 production; R=0.793, apoptosis ) with CD8CD38 expression. |
| 157 | MUTATIONS IN THE E2 AND NS5A PROTEIN OF HEPATITIS C VIRUS IN HIV-1 POSITIVE PATIENTS INFECTED WITH HCV GENOTYPE 3a European AIDS Conf 2001 Oct 28-31;8: (abstract no. 157) S Bagaglio1, A De Bona1, C Uberti Foppa1, MS De Mitri2, A Lazzarin1, G Morsica1 The number of mutations in the NS5A gene was not related with pre-treatment HCV viremia levels in both groups of patients, nor with CD4 cells number and HIV viral load in HIV positive individuals. Amino acid sequences analysis of E2 and NS5A regions did not show differentiation between sensitive and resistant strains in HIV positive patients infected with HCV genotype-3a. However, mutations within the ISDR of NS5A were frequently detected in SR and ETR patients with HIV infection. |
| 158 | COST ASSESSMENT OF ANTIRETROVIRAL DRUGS – IN PARTICULAR, NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NNRTI) - USED IN THE TREATMENT OF PATIENTS WITH HIV INFECTION European AIDS Conf 2001 Oct 28-31;8: (abstract no. 158) Sergio Sabbatani, Raffaella Cesari Within our patient cohort, with the exception of IND, PI’s lost ground progressively in favour of the two NNRTI drugs in the 3-year period considered. In particular, the average number of patients treated with NVP has increased. Moreover, the two TP’s where NVP is the 3rd drug are by far less expensive that the other TP’s; as a result, NVP appears to be one of the most interesting ARV drugs among those used as 3rd constituents in 3-drug combinations. As to EFAV, its actual role cannot be precisely defined as yet, since its routine use is too recent. However, the yearly cost per patient in the case of a ARV TP including EFAV as the 3rd drug is higher than TP’s which include NVP. |
| 159 | THE HOMOZYGOUS CCR5Δ32 GENOTYPE ACCOUNTS FOR HIGH RESISTANCE OF SOME INJECTING DRUG USERS (IDUs) TO HIV-1 INFECTION European AIDS Conf 2001 Oct 28-31;8: (abstract no. 159) G.S.Ryabov, Å.V.Kazennova, S.Ya.Zverev, V.V.Pokrovsky, À.F.Bobkov, J.N. Weber The homozygosity for the CCR5Δ32 allele accounts for high resistance of some exposed IDUs to HIV-1 infection. |
| 160 | IMPACT OF TREATMENT INTERRUPTION IN HIV INFECTED PATIENTS WITH VIROLOGICAL FAILURE European AIDS Conf 2001 Oct 28-31;8: (abstract no. 160) ML. Chaix1, C. Goujard2, L. Roudiere3, S. Gidrol1, MT. Rannou2, M. Burgard1, C. Rouzioux1 and JP. Viard3 Treatment interruption allowed reversion of major mutations in the RT and protease genes. Long term follow-up of patients is necessary to conclude on biological and clinical benefit of this strategy. |
| 161 | LOWER INCIDENCE OF THE M184V MUTATION IN PATIENTS RECEIVING COMBINATION THERAPY WITH EMTRICITABINE (FTC) COMPARED TO LAMIVUDINE (3TC) European AIDS Conf 2001 Oct 28-31;8: (abstract no. 161) Franck Rousseau Abstract withdrawn |
| 162 | ANTIVIRAL EFFICACY AND LOW RATE OF DEVELOPMENT OF RESISTANCE IN PATIENTS TREATED 1 YEAR FOR CHRONIC HBV INFECTION WITH FTC European AIDS Conf 2001 Oct 28-31;8: (abstract no. 162) F. Rousseau, L Fang, A Sykes, A Rigney, E Mondou Abstract withdrawn |
| 163 | PHARMACOKINETICS OF AMPRENAVIR AND LOPINAVIR IN COMBINATION WITH RITONAVIR AND NEVIRAPINE IN HIGHLY PRETREATED HIV INFECTED PATIENTS European AIDS Conf 2001 Oct 28-31;8: (abstract no. 163) Katja Römer*, Gerd Fätkenheuer*, Robert Kamps*, Bernd Salzberger*, David Burger# Combination therapy of amprenavir, lopinavir , ritonavir and nevirapine may result in unpredictable plasma concentrations of lopinavir. Interaction with nevirapine might be responsible for this phenomenon. Interestingly, this effect could not be corrected by the addition of ritonavir. Virological efficacy was low in these patients. Since in the scenario of salvage therapy with multiple underlying resistance mutations plasma concentrations of protease inhibitors should be as high as possible, pharmacological monitoring is advisable in patients treated with such combinations. |
| 165 | COMPARISON OF V3 LOOP SEQUENCES BETWEEN HIV-1 POSITIVE LONG TERM NON PROGRESSORS (LTNP) AND LATE STAGE PATIENTS (LSP) FROM RWANDA European AIDS Conf 2001 Oct 28-31;8: (abstract no. 165) F Roman, E Karita, E Fontaine, C Lambert, S Allen, F Schneider, R Hemmer, JC Schmit, V Arendt The V3 loop sequences of strains infecting LTNP showed a high frequency of very rare or new variants, compared to strains infecting LSP. These LTNP variants could represent specific patterns in HIV-1 strains infecting LTNP in Rwanda or could represent a response to stronger immune selection in LTNP |
| 166 | DT. DRUG RESISTANCE MUTATIONS AND OUTCOME OF SECOND-LINE TREATMENT IN PATIENTS EXPERIENCING THEIR FIRST PI-FAILURE ON NELFINAVIR CONTAINING HAART European AIDS Conf 2001 Oct 28-31;8: (abstract no. 166) BT Røge, TL Katzenstein, HL Nielsen, J Gerstoft In a substantial proportion of patients, experiencing failure on nelfinavir-containing HAART, no primary protease mutations could be detected. The study confirmed the frequent occurrence of D30N and the occasional detection of L90M reported by others. A pronounced accumulation of the secondary PI mutations N88D and M36I was found. At failure resistance to lamivudine, conferred by the RT mutation M184V, was almost complete. A high proportion of patients achieved viral loads below limits of detection on rescue regimens. |
| 490 | GENOTYPIC RESISTANCE IN GREEK NAÏVE HIV-POSITIVE PATIENTS European AIDS Conf 2001 Oct 28-31;8: (abstract no. 490) Mangafas N, Paraskevis D, Boboli M, Paraskeva D, Stamatopoulos E, Labropoulos L, Tjoumani A, Kremasmenou E, Hatzakis A, Lazanas M No primary mutations were found in the studied population. Secondary mutations were detected in half of the patients. No resistance to NNRTIs was detected. In case that these data are confirmed by further studies the antiretroviral combination in naïve patients may include an NNRTI. |
| 491 | SIDE-EFFECTS OF ANTIRETROVIRAL THERAPY IN GREEK HIV-POSITIVE POPULATION CAUSING DRUG INTERRUPTION: A COHORT STUDY European AIDS Conf 2001 Oct 28-31;8: (abstract no. 491) Mangafas N., Chini M., Kotsini V., Boboli M., Perdios G., Georgiou U., Paraskeva D., Lelekis M., Boutsikakis I., Sambatakou E., Gargalianos P., Saroglou G., Lazanas M. Adverse events, which lead to treatment interruption or change are frequent (37,3%). NRTIs are more frequently responsible for bone marrow suppression, peripheral neuropathy and diarrhea, Pis for gastrointestinal disorders, lipodystrophy, renal colic and nephrolithiasis and NNRTIs for allergic reactions. |
| 16 | PRE-TREATMENT WITH INTERFERON-ALPHA + RIBAVIRIN OF HIV-HCV COINFECTED PATIENTS APPEARS TO REDUCE HEPATOTOXICITY ASSOCIATED WITH SUBSEQUENT ANTIRETROVIRAL DRUGS European AIDS Conf 2001 Oct 28-31;8: (abstract no. 16) C. Uberti-Foppa, A.De Bona, R. Finazzi, G.Sitia, G.Morsica, E.Boeri, F.Veglia and A.Lazzarin Our data indicate that in HIV-HCV coinfected subjects with CAH, anti-HIV drug-induced hepatotoxicity is significantly reduced (from 2 to 3 times) by anti-HCV pretreatment, even in absence of a long-term hepatitis C virological response. |
| 17 | DIFFERENCES IN IMMUNOLOGIC PROGRESSION AMONG 7060 HIV-1 INFECTED INDIVIDUALS WITH KNOWN DATES OF SEROCONVERSION European AIDS Conf 2001 Oct 28-31;8: (abstract no. 17) Touloumi G1, Pantazis N1, Hatzakis A1, Porter K2, Babiker AG2 on behalf of CASCADE collaboration. Gender, exposure category, age at SC and presence of symptoms during acute HIV-1 infection influence the temporal trends in CD4 cell count during the HIV-1 incubation period. These results provide further information regarding factors that influence the HIV-1 disease progression and may indicate that closer monitoring is required before initiation of therapy. |
| 50 | DRUG RESISTANCE AT LOW VIREMIA IN TREATED HIV-1 INFECTED PATIENTS WITH CD4+ T CELL RESPONSE European AIDS Conf 2001 Oct 28-31;8: (abstract no. 50) Soo Aleman1, Karin Söderbärg2, Gisela Sitbon2,and Anders Sönnerborg Low viremia after initiation of therapy can thus be sufficient to generate viruses with several new mutations, which may lead to exhaustion of the future drug options. The increase in the viral load can though be limited and the CD4+ cell counts may continue to increase during emergence of these mutations. |
| 51 | BENEFIT OF POLYLACTIC ACID IMPLANT (NEWFILL) IN SEVERE FACIAL LIPOATROPHY IN HIV INFECTED PATIENTS: PRELIMINARY RESULTS OF THE VEGA STUDY European AIDS Conf 2001 Oct 28-31;8: (abstract no. 51) C Aubron-Olivier1, MA Valantin1, E Laglenne, M Pauchard1, P katz, D Costagliola2, C Katlama1 These preliminary data suggest that PLA (Newfill®) injections are a safe and effective symptomatic therapy in patients with severe facial LA. Durability of this effect will be evaluated at a two-year follow-up. |
| 52 | IMMUNE ACTIVATION CORRELATES BETTER THAN HIV PLASMA VIRAL LOAD WITH CD4 T-CELL DECLINE DURING HIV INFECTION European AIDS Conf 2001 Oct 28-31;8: (abstract no. 52) Z. Bentwich L. Qibin, G. Borkow, Z. Weisman, M. Stein, A. Kalinkovich These results suggest that: 1) Immune activation is a major, if not the dominant, determinant of CD4 decline, and should therefore be considered more important for the monitoring of HIV infection and its outcome following antiviral treatment. 2) Anergy, as manifested by CTLA-4 upregulation, may play a very important role in the immune reconstitution response to HAART. 3) Lack of such reconstitution may be overcome by correction of anergy, by various means, one of which may be the use of anti-CTLA-4 agents. |
| 54 | THE PHARMACOLOGIC BARRIER TO RESISTANCE: DIFFERENTIAL PATTERNS OF VIRAL EVOLUTION IN PROTEASE INHIBITOR NAÏVE AND EXPERIENCED PATIENTS DURING VIRAL REBOUND ON KALETRA (LOPINAVIR/R) THERAPY European AIDS Conf 2001 Oct 28-31;8: (abstract no. 54) S Brun1, D Kempf1, B Bernstein1, C Renz1, M King1, P Cernohous1, K Garren1, A Molla1, H Mo1, B Richards1, T Marsh1, C Deetz1, and E Sun1 Significant resistance mutations in protease were not detected in any ARV naïve pts. (n = 470) during 48 weeks or more of Kaletra therapy. In contrast, evolution in protease developed during viral rebound on Kaletra in 44% of PI-exp. pts. evaluated, all of whom had an erosion of their barrier to resistance. |
| 55 | LIVER INJURY IN HIV/HCV COINFECTED SUBJECTS INITIATING HAART IS NOT RELATED WITH A GREATER IMMUNE RECONSTITUTION NOR WITH AN INCREASE IN HCV REPLICATION European AIDS Conf 2001 Oct 28-31;8: (abstract no. 55) Martin-Carbonero L, Nunez M, Ríos P, Pérez-Olmeda M, Soriano V, González-Lahoz J. Out of 42 patients included in the study, 30 (72%) developed transaminase elevations of any grade, and it was severe in 6/42 (14%). The peak in liver injury appeared after a mean time of 6 months. Transaminases increase were not associated with CD4 counts, HIV-RNA and HCV-RNA viral loads and transaminase levels at baseline. Patients with less than 200 CD4 cells at baseline, did not develop transaminse elevation more frequently than the rest (72 % vs 72%), despite being immune reconstitution syndromes more frequently in them. |
| 56 | CHANGE IN THE INTERPRETATION OF RESISTANCE IN PATIENTS RECEIVING A RITONAVIR PLUS INDINAVIR-SALVAGE REGIMEN: THE IMPORTANCE OF PLASMA DRUG LEVELS European AIDS Conf 2001 Oct 28-31;8: (abstract no. 56) JL Casado, A Moreno, S Moreno, JL Blanco, A Antela, F Dronda, MJ Perez-Elias The combination of RTV+IDV exerts significant antiviral activity even in patients severely pretreated with protease inhibitors. The V82A mutation in combination with a large number of mutations was the best predictor of a lower rate of response, although there is a close relationship between plasma IDV levels, resistance assays, and virologic response. |
| 57 | A PHASE IV RANDOMISED, OPEN-LABEL, MULTICENTRE TRIAL TO EVALUATE SAFETY AND EFFICACY OF INDINAVIR/RITONAVIR (800/100 MG BID) VS. SAQUINAVIR/RITONAVIR (1000/100 MG BID) IN ADULT HIV-1 INFECTION: THE MaxCmin1 TRIAL European AIDS Conf 2001 Oct 28-31;8: (abstract no. 57) Ulrik Bak Dragsted, MD In this randomised trial, the preliminary results suggest that ritonavir-boosted PI treatment results in virological control in most patients and is reasonable well tolerated. Further, patients in the two study arms were well balanced for demographic, clinical, therapeutic and laboratory variables at baseline. Interim analyses of complete Week 24 efficacy and toxicity data – stratified for randomisation - will be presented. |
| 58 | CARDIOVASCULAR RISK-FACTORS IN HIV PATIENTS – ASSOCIATION WITH ANTIRETROVIRAL THERAPY. THE D:A:D STUDY European AIDS Conf 2001 Oct 28-31;8: (abstract no. 58) Nina Fris-Møller, MD A high proportion of persons on ART appear to be at risk for cardiovascular disease based on lipid profiles. This includes older subjects with preserved immunity, better viral suppression and evidence of lipodystrophy. Dyslipidaemia is more prevalent among patients receiving regimens containing PI or NNRTI’s and particularly if these drug classes are combined. The extent to which this leads to an accelerated development of CVD remains to be determined. CVD incidence data will be available in the third quarter of year 2002. |
| 59 | A RANDOMIZED TRIAL COMPARING CONTINUED INDINAVIR VS. SWITCHING TO INDINAVIR PLUS RITONAVIR IN HIV PATIENTS HAVING SUPPRESSED VIRAL LOAD WITH INDINAVIR PLUS TWO NUCLEOSIDE ANALOGUE REVERSE TRANSCRIPTASE INHIBITORS: THE BEST STUDY European AIDS Conf 2001 Oct 28-31;8: (abstract no. 59) Jan Gerstoft1, Josep Mallolas2, Jens Lundgren3, Gerd Faetkenheuer4, Antonella D’Arminio5, Francisco Antunes6, Peter Reiss7, Jose M Gatell2 The BEST study showed a better performance of continuing IDV tid versus switching to IDV/r (liquid) bid in suppressed stable patients. IDV/r bid can be a more convenient and equally effective option among those able to tolerate it or with the newer capsule formulation of RTV. |
| 60 | CD4 CHANGES DURING PLANNED TREATMENT INTERRUPTIONS ( THE SSITT TRIAL ) European AIDS Conf 2001 Oct 28-31;8: (abstract no. 60) C.Fagard1, A.Oxenius9, S. Yerly1, H. Gunthard5, A. Mc Lean9, M. Le Braz1, F. Garcia2, M. Plana2, J.M. Tiercy1, E. Bernasconi3, M.Battegay4, M. Fischer5, H.J.Furrer6, P. Vernazza7, A.Telenti8, R. Phillips9, B. Clotet2, T. Perneger1, L. Perrin1 and B. Hirschel1 During treatment interruption, CD4 cells fell markedly during the first 12 weeks, more so in patients with a high viral load. However, during the 12 subsequent weeks, CD4 counts remained stable. |
| 61 | BETTER VIROLOGIC SUPPRESSION AFTER SUBSTITUTION OF PROTEASE INHIBITORS WITH EFAVIRENZ IN PATIENTS WITH UNDETECTABLE VIRAL LOADS European AIDS Conf 2001 Oct 28-31;8: (abstract no. 61) C. Katlama1, A. Rachlis2, S. Staszewski3, S. Becker, J.F. Maa5, L.J. Bessen5, D.J. Manion5 & the Study 027 & 049 Teams EFV substitution of a PI maintains ARV suppression better than remaining on the protease containing regimen, with continued increases in CD4 counts. EFV substitution was also associated with improved adherence. This strategy may allow for improved long-term treatment success. |
| 62 | GIGHAART (ANRS 097) : A PROSPECTIVE RANDOMIZED TRIAL COMPARING THE EFFICACY OF A SALVAGE REGIMEN ADMINISTRED WITH OR WITHOUT TREATMENT INTERRUPTION IN PATIENTS WITH SEVERE BIOLOGICAL FAILURE AND EXTENSIVE PRIOR THERAPY European AIDS Conf 2001 Oct 28-31;8: (abstract no. 62) C. Katlama1, S. Dominguez1, C. Duvivier1, C. Delaugerre1, G. Peytavin2 , M. Legrand1, V. Calvez1, D. Costagliola3 and Gighaart Study Team. These interim analysis results demonstrate a significant benefit of treatment interruption followed by salvage therapy in patients with severe and multiple failure of antiretroviral therapy. |
| 63 | THE FRENCH HIV2 COHORT STUDY European AIDS Conf 2001 Oct 28-31;8: (abstract no. 63) Matheron S1, Pueyo S2, Damond F3, Campa P1, Simon F, Chene G2, Brun-Vezinet F, and the French HIV-2 cohort study group. Follow-up data of this cohort show that plasma HIV2-RNA is predictive of clinical progression in patients without severe immunodeficiency, useful to determine the frequency of subsequent clinical and immunological follow-up and therapeutic indications. |
| 64 | BASELINE AND WEEK 24 GENOTYPIC ANALYSES OF HIV FROM ANTIRETROVIRAL-EXPERIENCED PATIENTS ADDING TENOFOVIR DF THERAPY European AIDS Conf 2001 Oct 28-31;8: (abstract no. 64) M.D. Miller, N. Margot, L. Naeger, D. Coakley and A. Cheng Once daily TDF 300 mg showed significant and durable HIV RNA reductions through week 24 among ART-experienced patients with TAMs, M184V, or both types of RT mutations. There was infrequent development of tenofovir-associated mutations and reduced development of protease inhibitor-associated mutations. |
| 65 | ATAZANAVIR (BMS-232632): 48-WEEK SAFETY AND EFFICACY VS NELFINAVIR, EACH IN COMBINATION WITH STAVUDINE AND LAMIVUDINE, IN TREATMENT-NAIVE, HIV-POSITIVE SUBJECTS (AI424-008) European AIDS Conf 2001 Oct 28-31;8: (abstract no. 65) G. Pantaleo,1 I. Sanne,2 P. Cahn,3 L. Percival,4 P. Phanuphak,5 T. Kelleher,4 I. Wellens,6 M. Giordano4 TAZ is safe, well-tolerated, and effective in rapidly reducing and maintaining suppression of HIV RNA, as well as increasing CD4 cell count in treatment-naïve HIV-positive subjects. Moreover, TAZ does not elevate TC, LDL, and TG concentrations as is commonly seen with current PIs and non-nucleoside reverse transcriptase inhibitors. This advantage suggests that TAZ does not lead to dyslipidemia in treatment-naïve subjects and may be associated with a reduction in the cardiovascular risk that is associated with dyslipidemia in this population. |
| 67 | VIRAL REBOUND AFTER SUPPRESSION BELOW 400 COPIES/ML ON INITIAL HAART REGIMENS, ACCORDING TO PRIOR NUCLEOSIDE EXPERIENCE AND DURATION OF SUPPRESSION European AIDS Conf 2001 Oct 28-31;8: (abstract no. 67) Phillips AN, Staszewski S*, Lampe F, Youle M, Klauke S*, Bickel M*, Sabin C, Doerr HW*, Johnson M, Loveday C, Miller V* The rate of rebound declines substantially over increasing time with viral suppression on HAART in both prior-nuc experienced and prior naïve patients. However the markedly increased rate of viral rebound experienced by people who took nucleosides prior to HAART persists even after 2 years of prolonged suppression. This disadvantage seems to be apparent even in those with < 2months prior nuc use before HAART. In fact the extent of the disadvantage does not increase with increasing prior nucleoside expeosure over about 6 months. One possible explanation is a rapid build-up during nucleoside mono or dual therapy of an archive of viral sub-species with nucleoside resistance mutations which persist in some form (e.g.: latently infected CD4 cells) for several years. |
| 68 | ASSOCIATION BETWEEN THE LEVEL OF PLASMA HIV RNA AND LONG-TERM INCREASE OF CD4+ CELL COUNTS IN A COHORT OF HIV-INFECTED PATIENTS INITIATING A PROTEASE INHIBITOR-CONTAINING REGIMEN European AIDS Conf 2001 Oct 28-31;8: (abstract no. 68) V Le Moing*1,2, R Thiebaut2, C Leport1, P Carrieri3, A Devidas4, D Costagliola5, C Cazorla6, F Brun-Vézinet1, F Raffi7, G Chêne2 and the APROCO Study Group Early achievement and long-term maintenance of complete viral response are associated with the highest long-term increase of CD4 in pts treated with HAART. However, when viral response is not sustained, a continuous increase of CD4 may be achieved if VL remains <10,000 copies/ml. |
| 69 | QUANTIFICATION OF HUMAN HERPESVIRUS-8 (HHV-8) BY REAL-TIME POLYMERASE CHAIN REACTION IN BLOOD OF AIDS PATIENTS WITH KAPOSI’S SARCOMA AND MULTICENTRIC CASTLEMAN’S DISEASE European AIDS Conf 2001 Oct 28-31;8: (abstract no. 69) J.P. Routy1, S. Côté2, N. Cloutier2, Y. Abed2, M. Maguigad1, G. Boivin2 The pathogenesis of KS and MCD is different since only MCD is associated with an important viremia. |
| 70 | IN VIVO INTERACTION BETWEEN RIBAVIRIN AND D4T IN HIV-HCV COINFECTED PATIENTS TREATED BY D4T HAS NOT SHORT TERM IMPACT ON HIV RNA LEVELS European AIDS Conf 2001 Oct 28-31;8: (abstract no. 70) D. Salmon1, S. Perusat2, J. Grassi3, F. Lunel4, JM Pawlotsky5, B. Silbermann1, F. Bonnet6, R. Lassalle2, G. Chêne2 and ANRS The coprescription of ribavirin and D4T does not seems to have any short impact on HIV viral load. However, a careful surveillance is needed when D4T, as well as AZT having a similar metabolic pathway, is coprescribed with ribavirin. |
| 73 | STUDY OF 42 CASES OF INFECTIVE ENDOCARDITIS IN HAART ERA European AIDS Conf 2001 Oct 28-31;8: (abstract no. 73) Valencia ME, Ortega G, # Guinea J, Moreno V, González Lahoz J. IVDA are the most important risk group for acquiring HIV and HCV, and developing IE in Spain. In the HAART era, the frequency of IE has dismissed and most of the cases are seen in patients without HAART. In HIV (+) patients, IE is usually reported in early stages and apparently HIV has no influence on clinical manifestations, but mortality is more elevated in this group. Instead of the decrease in the number of cases, IE is, in HAART era, an important disease with an elevated mortality rate in patients with HIV infection. |
| 74 | ONE WEEK OF MONOTHERAPY WITH TMC125, A NOVEL HIGHLY POTENT NNRTI, PRODUCES A MEAN 2-LOG REDUCTION IN VIRAL LOAD IN ANTIRETROVIRAL-NAÏVE, HIV-1 INFECTED VOLUNTEERS European AIDS Conf 2001 Oct 28-31;8: (abstract no. 74) B. Gruzdev1, A. Rakhmanova2, G. van’t Klooster3, K. De Dier3, S. Comhaire4, P. Baede-Van Dijk5, M.P. de Béthune3, and R. Pauwels3 TMC125 (R165335) is a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) with equipotent in vitro activity (EC50 = 1-10 nM) against wild-type HIV-1 and NNRTI-resistant variants encoding L100I, K103N, Y181C, Y188L or G190A/S mutations. |
| 75 | OUTCOME OF PATIENTS TREATED DURING PRIMARY HIV-1 INFECTION: 5- YEAR FOLLOW-UP European AIDS Conf 2001 Oct 28-31;8: (abstract no. 75) Samir Vora1 Sabine Yerly1, Veronique Schiffer1, Jean-François Balavoine2, Laurent Kaiser1, Luc Perrin1 After a 5-year follow-up all patients that initiated treatment at the time of PHI are still on antiretroviral therapy and 80 % have plasma HIV-viremia < 100 copies/mL. However, no decrease in HIV-1 cell-associated DNA and RNA has been observed which is evidence of persistent viral replication based on the detection of low levels of full length gag mRNA in PBMC. CD4+ cell counts are within the normal range in these patients. |
| 190 | TENOFOVIR DF: A 24-Week INTERIM ANALYSIS FROM A PHASE III RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY IN ANTIRETROVIRAL EXPERIENCED PATIENTS European AIDS Conf 2001 Oct 28-31;8: (abstract no. 190) A.L. Pozniak1, A. Plettenberg2, W.Rozenbaum3, A.Sonnerborg4, J.M.Molina5, J.Gatell6, S.S. Chen7, J. Salzer7, D. Coakley7, M.D. Miller7, B.P. Kearney7 and A. Cheng7 for the Study 907 Team Through 24 weeks, once daily tenofovir DF 300 mg provides a consistent pharmacokinetic profile, significant antiviral suppression in highly treatment experienced patients and a safety profile which is similar to placebo. |
This information is designed to support, not replace, the relationship that exists between you and your doctor.
©1980, 2003. AEGiS.